Maxim Group Initiates Coverage on InspireMD (NYSE:NSPR)

Maxim Group started coverage on shares of InspireMD (NYSE:NSPR) in a research report issued to clients and investors on Monday, MarketBeat reports. The firm set a “buy” rating and a $6.00 price target on the stock. Maxim Group’s price target indicates a potential upside of 265.85% from the stock’s current price.

InspireMD Trading Up 0.6%

InspireMD stock opened at $1.64 on Monday. InspireMD has a 12-month low of $1.51 and a 12-month high of $3.80. The firm has a 50-day moving average price of $1.82 and a 200-day moving average price of $2.15. The firm has a market capitalization of $69.49 million, a PE ratio of -2.19 and a beta of 0.72.

Insider Buying and Selling at InspireMD

In other news, insider Shane Thomas Gleason sold 17,593 shares of the stock in a transaction that occurred on Wednesday, January 21st. The stock was sold at an average price of $1.62, for a total value of $28,500.66. Following the sale, the insider directly owned 1,174,664 shares in the company, valued at approximately $1,902,955.68. This represents a 1.48% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Insiders sold 61,194 shares of company stock valued at $99,188 in the last quarter. Corporate insiders own 34.06% of the company’s stock.

Hedge Funds Weigh In On InspireMD

Hedge funds have recently bought and sold shares of the business. Rosalind Advisors Inc. lifted its position in shares of InspireMD by 70.6% during the third quarter. Rosalind Advisors Inc. now owns 3,905,743 shares of the company’s stock worth $9,413,000 after purchasing an additional 1,616,644 shares during the last quarter. Nantahala Capital Management LLC grew its holdings in shares of InspireMD by 45.7% in the third quarter. Nantahala Capital Management LLC now owns 3,376,484 shares of the company’s stock worth $8,137,000 after purchasing an additional 1,058,467 shares during the last quarter. Aberdeen Group plc increased its stake in InspireMD by 27.9% in the 4th quarter. Aberdeen Group plc now owns 3,173,364 shares of the company’s stock worth $5,649,000 after buying an additional 692,247 shares during the period. Parkman Healthcare Partners LLC lifted its holdings in InspireMD by 97.6% during the 3rd quarter. Parkman Healthcare Partners LLC now owns 2,440,633 shares of the company’s stock valued at $5,882,000 after buying an additional 1,205,328 shares in the last quarter. Finally, Velan Capital Investment Management LP boosted its position in InspireMD by 137.1% in the 3rd quarter. Velan Capital Investment Management LP now owns 2,143,698 shares of the company’s stock valued at $5,166,000 after buying an additional 1,239,669 shares during the period. Institutional investors own 44.78% of the company’s stock.

Trending Headlines about InspireMD

Here are the key news stories impacting InspireMD this week:

• Positive Sentiment: Maxim Group initiated coverage with a “Buy” rating and a $6.00 price target (well above the current trading level), which appears to have driven investor interest and buying pressure. Read More.
• Positive Sentiment: Recent filings and reports show several institutional investors increased positions in prior quarters (Rosalind Advisors, Nantahala, Aberdeen, Parkman, Velan), signalling continued institutional interest that can support the stock over time. Read More.
• Neutral Sentiment: Company fundamentals/technical backdrop remains mixed: small market cap (~$69M), negative P/E, current price below the 50- and 200-day moving averages — factors that increase risk and may limit upside until clinical/commercial catalysts appear.
• Negative Sentiment: Insider Shane Thomas Gleason has sold a material series of shares between Jan. 15 and Feb. 2 — roughly 61,000 shares at average prices in the ~$1.57–$1.66 range — which can create selling pressure and signal lack of insider accumulation into the rally. The sales are disclosed in SEC filings. Read More.

InspireMD Company Profile

InspireMD, Inc is a medical device company focused on developing next-generation stent technologies for cardiovascular and neurovascular interventions. The company’s core innovation lies in its MicroNet® mesh platform, a proprietary nanostructured covering designed to prevent embolic events during stent implantation. By integrating this fine mesh into traditional stent architectures, InspireMD aims to enhance safety and efficacy in the treatment of carotid artery disease and other vascular pathologies.

The company’s flagship offering, the CGuard® Embolic Prevention System (EPS), has received CE Mark approval and is commercially available in multiple international markets.